Saluda Medical’s Post

Let's Connect at Boston MedDevice to learn how Puerto Rico's Medical Device Ecosystem is the ideal place for your organizations growth. From R&D to Full commercialization we have it all in Puerto Rico. "It's not what's next in Medical Device, it's where"

Johnson & Johnson announced their acquisition of Shockwave Medical for $13.1 billion in April 2024. - You're a pre-commercial start-up in the same space. What do you do? How does this affect you? Does this validate the market or make it more difficult? Do you have to change your commercialization strategy? Do you have to accelerate? - That's the thing about the team at Amplitude Vascular Systems. They are a pre-commercial start-up. But they don't act like it. We dig into one of the biggest stories in medical devices this year with Sean Gilligan and Robert Chisena. - MassMEDIC Boyd Biomedical

A few thoughts from the top of the morning here: In just a little over a year, J&J has gone from Mr./Mrs. Irrelevant to perhaps the compelling suite of products in the Cardiac/Vascular market. Pretty Impressive. Hopefully J&J continues to leave Abiomed alone, and does so with Shockwave...a la what they did w/ Biosense Webster. If they go in and J&J'ify everything, innovation will stop faster than a production line with a wrench tossed in it's gears. If Shockwave's acquisition of Neovasc, a coronary sinus reducer for refractive angina ever bears any fruit...$13.1 B will seem like a song for this acquisition. J&J means business this time. They have often said they wanted to become a major player again in Cardiac/Vascular, dating back to their once imminent acquisition of Guidant. But actions speak louder than words. They are likely far from done. Percutaneous valve technologies are the glaring omission from their shiny new product portfolio. An acquisition of Edwards would be the lynch pin here, striking fear in the hearts and minds of Hospital Purchasing execs across America. Or maybe they start small, acquiring some of the earlier stage companies that are showing positive results from first in man trials across the various markets: Aortic, Mitral & Tricuspid? Maybe they look at the one "non strategic owned" commercial stage perc valve company on the market as an entry point? Time will tell, fun to speculate...

🎯 For those pre-commercial MedTech companies out there: Monica Wellejus from Ossiform highlights the importance of engaging knowledgeable advisors and collaborating closely with surgeons from the early stages of product development. The value of early market feedback to identify desired product features but also to uncover potential obstacles to future adoption by surgeons cannot be understated!

Transitioning from MedTech Sales to Scalable Sales: Earning Attention and Building Trust. I want my med tech legacy to be: he tried to prepare us to sell outside of the med tech matrix. 25-26 October you may consider joining the Content Crib 2.0 in Bentonville, Arkansas. Unlike any meeting. 1 day 1/2 day focused on how med tech & surgeons can learn how to earn attention and build trust with Brand Story Selling practices. We cap the meeting at 50 people total. We can put your name on a waiting list if you don’t act in time. Registration located in comment section below.

The Australian Competition and Consumer Commission (ACCC ) has announced its decision not to oppose Cochlear's proposed acquisition of the cochlear implants business of Oticon Medical from its parent company, Demant. #ACCC #Cochlear #OticonMedical #Demant #BusinessAcquisition #CompetitionRegulation #HearingTechnology #MarketConsolidation #RegulatoryApproval #BusinessDeal

I learned some important lessons. Launching Dr. Yglo felt impossible at first. The new Medical Device Regulations (MDR) looked like mountains, and competitors seemed to be everywhere. But we refused to give up. We talked to experts to support us and give us guidance. A lot... Our experience helped, and speed became our secret weapon. We partnered with local distributors. Our plug-and-play formula was a game-changer. Three months later, we launched. I learned that open communication kept us going. And, of course, persistence made it real. Now, Dr. Yglo is here. What personal learning made your product launch successful?  Let me know in the comments.  #dream #otc #selfcare

Extending Lives, Expanding Possibilities. That's the newly announced mission for Vantive, Baxter International Inc.'s proposed kidney care and acute therapies company that is expected to either be spun-off or sold later this year. The Vantive logo includes a "V" motif divided into three parts to represent the innovative therapies, digital solutions, and advanced services the company delivers. The logo is depicted in the color plum, leveraging the stability and trustworthiness of blue, Baxter’s primary brand color, combined with the energy and boldness of red. What do you hope to see from Vantive in 2025 and beyond? What do you hope the next 70 years of Baxter looks like? #healthcare #innovation #technology #medtech Read the full press release: https://lnkd.in/eFbSJ343 *** I'll be covering more on this front in a future Signals piece. This will be included in my monthly recap of headlines, research, funding and market movers that goes out later this week. Get it here: 📡 trfitzpatrick.com

Exciting News: Johnson & Johnson is in talks to acquire Shockwave Medical, a prominent cardiovascular device maker. This potential deal, anticipated to be finalized soon, emphasizes J&J's commitment to bolstering its medical-device division. Shockwave's market value surged from $11 billion to nearly $12 billion following the report, with its 2024 revenue projections showing a promising 27% increase from the previous year. Notably, J&J's recent $16.6 billion acquisition of Abiomed connects the companies, highlighting synergy in the sector. Joaquin Duato, J&J's CEO, aims for aggressive acquisitions in the medical-device sector, following a sales rebound post-pandemic. J&J is set to report its quarterly results on April 16. The uptick in healthcare M&A activities, up by 51% this year, reflects the industry's growth and resilience. Darin W. White